Highest-materiality recent filing
Cullinan's zipalertinib combo meets PFS endpoint in Phase 3 REZILIENT3 trial
REZILIENT3 Phase 3 trial (285 patients) met primary endpoint of PFS at planned interim analysis; statistically significant and clinically meaningful improvement.
Cullinan Therapeutics Q2 2026 net loss $53.7M; cash $356M; pipeline on track
Net loss $53.7M vs $70.1M YoY; R&D expenses $44.4M vs $61.0M; G&A $12.8M vs $14.8M.
Cullinan Therapeutics reports annual meeting results; all proposals approved
Shareholders elected Nadim Ahmed and Stephen Webster as Class III directors for three-year terms.
CLN-978 achieved DAS28-ESR remission in a rituximab-refractory RA patient, reducing score from 4.0 to 2.2 at week 4.
In SLE (n=18), 10 of 14 patients (71%) with ≥4 weeks follow-up achieved ≥4-point hSLEDAI reduction; 5 attained DORIS remission.
Cullinan reports initial Phase 1 data for CLN-978: B cell depletion and early efficacy in RA/SLE
As of Jan 14, 2026 cutoff, 14 patients dosed (5 RA, 9 SLE) across cohorts 1-3.
Net loss of $49.7M for Q1 2026 vs $48.5M in Q1 2025; R&D expense $42.1M, G&A $11.6M.
Cullinan reports $439M cash, $219.9M net loss; CLN-978 data and zipalertinib NDA on track
Cash and investments of $439.0M as of Dec 31, 2025; runway into 2029.
Preliminary cash, equivalents, investments, interest receivable $439.0M at Dec 31, 2025; runway into 2029.
Cullinan Therapeutics reports 31% CR/CRh rate at 12 µg/kg for CLN-049 in R/R AML Phase 1
At 12 µg/kg (n=16), CR/CRh rate 31% (5/16) and CRc rate 31% (5/16); at ≥6 µg/kg (n=32), CR/CRh 25% and CRc 28%.
Cullinan Therapeutics terminates exclusive MIT license for CLN-617; program abandoned
Terminates Exclusive Patent License Agreement with MIT for CLN-617, effective Feb 18, 2026.
Cullinan Q3 net loss $50.6M; focuses on T cell engagers; cash runway into 2029
Net loss $50.6M vs $40.6M YoY; R&D expense $42.0M, G&A $13.6M.
Cullinan reports Phase 1 CLN-049 data: 31% CRc at 12 μg/kg in r/r AML
Anti-leukemic activity at doses ≥6 μg/kg: CRc 30%, ORR 57% (n=23); at 12 μg/kg CRc 31%, ORR 69% (n=13).
Cullinan Therapeutics revises CLN-978 SLE data timing to H1 2026
Initial clinical data for CLN-978 in systemic lupus erythematosus now expected in first half of 2026.
Cullinan Q2 net loss $70.1M, cash $510.9M; appoints new directors; CLN-978 enrolling
Q2 2025 net loss $70.1M vs $42.0M; R&D expenses $61.0M vs $36.3M; cash and investments $510.9M providing runway into 2028.
Cullinan Therapeutics annual meeting results: all proposals pass, directors elected
Elected Class II directors: Anthony Rosenberg, David P. Ryan, Mary Thistle; each received >47M votes for.
Upfront license fee of $20 million; Genrix eligible for up to $292M in development/regulatory milestones and up to $400M in sales-based milestones.
Cullinan Q1 net loss $48.5M; CLN-978 gains EMA approval for RA, expands into Sjögren's
Net loss of $48.5M in Q1 2025 vs $37.1M in Q1 2024; R&D expenses rose to $41.5M.
Cullinan Therapeutics reports Q4/FY 2024 results; zipalertinib pivotal study met endpoint
Cash and investments of $606.9M at Dec 31, 2024; runway extended into 2028.
REZILIENT1 trial met primary endpoint of overall response rate in NSCLC with EGFR exon 20 insertion mutations after prior therapy.
Cullinan Therapeutics Q3 net loss $40.6M; cash $639M; CLN-978 IND cleared for SLE Phase 1
Net loss $40.6M ($0.69/sh) vs $39.2M ($0.91/sh) in Q3 2023; cash $639M provides runway to 2028.
Cullinan Therapeutics receives FDA IND clearance for CLN-978 in moderate-to-severe SLE
FDA cleared IND for CLN-978, a CD19 T cell engager, in systemic lupus erythematosus.
Cullinan Therapeutics receives Australian HREC approval to start Phase 1 SLE trial of CLN-978
HREC approval in Australia to initiate global Phase 1 trial of CLN-978 for systemic lupus erythematosus (SLE).
Cullinan Q2 net loss $42M; cash $664.9M; advancing CLN-978 IND in SLE for Q3 2024
Net loss $42.0M vs $32.2M Q2 2023; R&D $36.3M, G&A $13.8M; cash runway into 2028.
Anne-Marie Martin elected with 25,054,060 votes for, 11,471,277 withheld, 4,156,894 broker non-votes.
Cullinan reports Phase 2b zipalertinib data: 39% ORR in post-amivantamab NSCLC patients
ORR of 39% (confirmed) and DCR of 94% in 18 evaluable patients; median DOR and PFS not yet reached.
Cullinan announces CLN-619+Keytruda shows PRs in EGFR/ALK NSCLC; monotherapy CR in parotid
Combination with pembrolizumab: 3 confirmed PRs in NSCLC (EGFR/ALK) and gastric patients typically CPI-unresponsive.
Cash, cash equivalents, investments $434.8M as of March 31, 2024; plus $280M April private placement extends cash runway into 2028.
Cullinan Therapeutics hires Mary Kay Fenton as CFO; $495k salary, 200k-share option grant
Mary Kay Fenton appointed CFO effective April 29, 2024; previously CFO of Talaris Therapeutics.
Cullinan raises $280M, pivots to autoimmune with promising CLN-978 data; cash runway into 2028
$280M private placement at $19/share; pre-funded warrants $18.999; extends cash runway into 2028.
Cullinan Oncology reports Q4 2023 net loss of $25.6M; CFO Trigilio to depart Mar 29
Net loss for FY 2023 was $155.1M vs income of $109.2M in 2022; Q4 loss $25.6M.
Cullinan Oncology reports $468.3M cash; runway into H2 2026 unchanged
Preliminary unaudited cash, equivalents, investments, and interest receivable totaled $468.3M as of Dec 31, 2023.
Cullinan Oncology reports $468.3M cash as of Dec 31, 2023; runway into H2 2026
Unaudited cash, equivalents, investments, and interest receivable totaled $468.3M as of Dec 31, 2023.
Cullinan Oncology reports Q3 net loss of $39.2M; cash runway extends to H2 2026
Cash and investments $481.9M at Sept 30, 2023; runway extended into H2 2026 from prior into 2026, driven by $38M ATM net proceeds and higher interest income.
Cullinan Oncology Q2 2023: Net loss $32.2M; cash $512.1M; pipeline advances with Phase 3 start
Cash and investments $512.1M as of June 30, 2023; expected runway into 2026.
Cullinan Oncology transitions CSO Patrick Baeuerle to advisor; stockholders elect directors
Dr. Baeuerle transitions from Chief Scientific Officer to Co-Founder & Chief Scientific Advisor, effective June 8, 2023.
CLN-619 monotherapy showed 1 complete response (parotid gland cancer) and 2 unconfirmed partial responses (endometrial cancer) in heavily pre-treated patients.
Cullinan Oncology Q1 net loss $58.1M; cash $503.5M; zipalertinib dose change
Net loss $58.1M for Q1 2023 vs $27.1M in Q4 2022; R&D expenses $52.1M including $25M upfront for CLN-418 license.
Cullinan Oncology reports Q4 net loss of $27.1M; licenses CLN-418; cash runway into 2026
Cash and investments $550.1M as of Dec 31, 2022; cash runway expected into 2026.
Cullinan licenses U.S. rights to B7H4 x 4-1BB bispecific CLN-418 from Harbour; cash runway into 2026
Upfront $25M; up to $148M dev/reg milestones + $415M sales milestones plus tiered royalties up to high teens.
Cullinan Oncology exchanges 6.5M common shares for Series A convertible preferred held by BVF funds
Exchanged 6,475,000 common shares for 647,500 Series A convertible preferred (10:1 conversion ratio).
Cullinan Oncology reports Q3 net loss $24.9M; initiates pivotal zipalertinib study
Initiated pivotal study for zipalertinib in EGFR exon 20 NSCLC; cohort to evaluate 150 mg BID with food.
David P. Ryan appointed to board; Ansbert Gadicke resigns as director at Cullinan Oncology
David P. Ryan, M.D. appointed as Class II director effective Nov 1, 2022.
Cullinan Oncology increases ownership in MICA subsidiary to 92% for $30.7M
Purchased 14.97M shares from Avalon Ventures and Bregua Corp at $2.05/share, totaling $30.7M.
Cullinan Oncology reports Q2 2022 net income of $174.1M, cash runway through 2026 after Taiho deal
Cash and investments $656M as of June 30, 2022; expected to fund operations through 2026.
Cullinan Oncology closes $275M sale of Cullinan Pearl to Taiho; co-development deal for CLN-081
Upfront cash payment of $275M from Taiho; potential $130M in regulatory milestones for CLN-081/TAS6417.
Cullinan Oncology shareholders re-elect Gadicke and Rosenberg as directors, ratify KPMG
Ansbert Gadicke elected with 27,033,605 votes for, 10,667,725 withheld, 4,141,978 broker non-votes.
Cullinan Oncology Q1 net loss $12.9M; Taiho deal adds $275M, extends cash runway through 2026
Cash and investments $410M at March 31, 2022; $685M including $275M Taiho upfront; runway extended to 2026.
Cullinan Oncology sells Cullinan Pearl to Taiho for $275M; co-develop CLN-081 in U.S.
Taiho will acquire Cullinan Pearl for $275M upfront, plus up to $130M in regulatory milestones.
Cullinan Oncology reports Q4 2021 net loss of $34.4M; cash $430.9M through 2024
Net loss $34.4M in Q4 2021 vs $18.4M in Q3 2021; FY 2021 net loss $67.5M vs $59.5M in FY 2020.
the Board of Directors (the “Board”) of the Company appointed David Meek as a Class I director, effective May 15, 2024.
Thomas Ebeling notified the Board of his intention to serve out his current term and resign as a director effective as of June 26, 2024.
On April 29, 2024, Cullinan Therapeutics, Inc. (the “Company”) announced the hiring and appointment of Mary Kay Fenton as the Company’s Chief Financial Officer, effective immediately.
Upon mutual agreement between Patrick Baeuerle and Cullinan Oncology, Inc. (the “Company”), Dr. Baeuerle will transition from Chief Scientific Officer of the Company to Co-Founder, Chief Scientific Advisor of the Company effective June 8, 2023.
Ansbert Gadicke, M.D. notified the Board of his intention to resign as a director effective as of November 1, 2022.
appointed David P. Ryan, M.D. as a Class II director, effective immediately.
On February 28, 2022, Cullinan Oncology, Inc. (the “Company”) announced the hiring and appointment of Jeffrey Jones, M.D., MPH, MBA as the Company’s Chief Medical Officer, effective immediately.
On December 27, 2021, Morana Jovan-Embiricos notified the Board of Directors of Cullinan Oncology, Inc. (the “Company”) of her intention to resign as a director effective as of December 31, 2021
Mr. Hughes’ last date of employment with the Company as its President and Chief Executive Officer is October 18, 2021
the Board appointed Mr. Ahmed as a Class III director of the Company, effective as of October 18, 2021
the Board appointed Nadim Ahmed as President and Chief Executive Officer of the Company, effective as of October 18, 2021
Max materiality 0.90 · Median 0.68 · Most common event earnings